drugset
drugset / Trial / NCT03630939

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

NCT03630939 ↗

Phase 1/2 Completed 104 enrolled Escalier Biosciences B.V. Innovaderm Research Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).

Timeline

Start
2018-08-09
Primary completion
2019-06-05
Completion
2019-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ESR-114 Unknown 1.5 % Topical
Subject ESR-114 Unknown 5 % Topical

Indications

psoriasis